Treatment
Camrelizumab clinical trials
We’re tracking 100 recruiting studies that include Camrelizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05738434RecruitingPhase 2
Testing immunotherapy plus targeted drug with short chemo for esophagus cancer
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
Zhengzhou, HenanAges 18–75 - NCT05789043RecruitingPhase 3
Test of immunotherapy plus pills and chemotherapy for advanced melanoma
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
BeijingAges 18 years+ - NCT06438627RecruitingPhase 3
New triple therapy vs standard for advanced nasopharyngeal cancer
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
Guangzhou, GuangdongAges 18–65 - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07787273RecruitingPhase 2
Combination therapy before surgery for esophageal cancer
This trial tests a combination of two drugs (interferon gamma and camrelizumab) given before surgery for a certain type of esophageal cancer. It aims to see if this combination can shrink the tumor and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT06669611RecruitingPhase 3
Comparing two drug combos for advanced nasopharyngeal cancer
This trial tests whether a new drug combination (Nab-Paclitaxel with Camrelizumab) works better than the standard GP chemotherapy plus Camrelizumab for people whose nasopharyngeal cancer has come back or spread. The goal is to find a more effective treatment option.
Guangzhou, GuangdongAges 18 years+ - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT07267806RecruitingPhase 3
Camrelizumab and Apatinib with or without chemo for advanced liver cancer
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
Guangzhou, GuangdongAges 18 years+ - NCT06901622Enrolling by invitationPhase 2
Testing a combination of drugs for advanced gallbladder and bile duct cancer
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
ZhengzhouAges 18–75 - NCT05139095RecruitingPhase 2
Camrelizumab plus apatinib for high-risk pregnancy tumor
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
BeijingAges 18–60 - NCT04944914RecruitingPhase 3
Camrelizumab with targeted radiation for limited nasopharyngeal cancer spread
This trial tests whether combining camrelizumab (an immune medicine) with stereotactic body radiotherapy (high-precision radiation) works better than camrelizumab alone. It’s for people whose nasopharyngeal cancer has spread to a small number of spots in the body and may help control those metastases longer.
Guangzhou, GuangdongAges 18–70 - NCT04481763RecruitingPhase 1/Phase 2
Camrelizumab plus radiation for early triple-negative breast cancer
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
Nanchang, JiangxiAges 18–75 - NCT05202314Recruiting
Camrelizumab plus chemo after stent for left bowel cancer
This study tests whether adding camrelizumab (an immune therapy) to chemotherapy—after a stent is placed to open a blocked left-sided colon—improves outcomes. It’s meant for people whose cancer can still be removed with surgery after the blockage is treated.
Beijing, Beijing MunicipalityAges 18–80 - NCT05761470RecruitingPhase 2
Test before-surgery cancer treatment for breast tumors with DNA repair gene changes
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
Guangzhou, GuangdongAges 18–75 - NCT05825443RecruitingPhase 2
Chemo plus immunotherapy after lung surgery
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
Guandong, GuangdongAges 18–80 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05624099RecruitingPhase 2
Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
FuzhouAges 18–75 - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06241807RecruitingPhase 2
Camrelizumab plus chemo before surgery for stage III lung cancer
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
Jinan, ShandongAges 18–75
What Camrelizumab is being studied for
Conditions with recruiting Camrelizumab studies.
Common questions
- Are there clinical trials studying Camrelizumab?
- Yes. Clin2 currently lists 100 recruiting studies that include Camrelizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Camrelizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Camrelizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Camrelizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.